I bought into the rights issue. It is very cheap and trading like it is friendless in a bear market.
This trial is about expanding the use, the label of OncoSil.
in the US and Australia most patients get a chemo called Abraxane. It is patented and is covered by insurance in these countries.
There is another older chemo that is stronger and much more side effects, Falforinox. This is used widely in Europe and is what insurance pays for in Europe.
The original approval that I understand is using Oncosil alongside Abraxane. So a post approval trial is now with Falforinox as well as Abraxane.
Also I notice this trial is for local advanced pancreatic cancer patients. Question is the data on patients that have their cancer matastised.
These post approval trials will get more doctors familiar with using Oncosil, they can then tell new patients that might not precisely fit on the "label" that they should use it. Its off label use. It is how Sirtex Medical was able to get levearge in Europe when they first got approved.
This will take 12 months to materialise in sales however.
OSL Price at posting:
1.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)